Agreement with Australia’s leading Men’s Health Pharmacy for access to SPONTAN®
LTR Pharma is pleased to announce it has entered into an access agreement with Men’s Health Downunder (MHDU) to facilitate access to SPONTAN® through the Therapeutic Goods Administration’s (TGA) Special Access Scheme. MHDU is a specialised men’s health provider operating a multidisciplinary network of healthcare professionals. The partnership has already achieved its first milestone, with […]
The Australian | LTR Pharma inks deal with men’s health provider for ED therapy
LTR Pharma new access agreement with Mens Health Downunder to facilitate supply of SPONTAN has been featured in a Special Report in The Australian newspaper, highlighting the significant unmet need for fast-acting and effect treatments for Erectile Dysfunction. “MHDU founder and executive chairman Brad Butt said the collaboration with LTR Pharma enhances its ability to […]
Early Launch of Online Men’s Health Platform
LTR Pharma’s joint venture partner Restorative Health Clinic has today launched its online men’s health platform ahead of schedule, delivering comprehensive telehealth services to Australian men. The platform combines clinical expertise in men’s health with access to innovative treatments, including SPONTAN®, providing Australian men with convenient access to healthcare professionals and evidence-based treatments. Australian men […]
VIDEO | Break it Down: Quick access to quick ED fix from LTR Pharma
Stockhead TV’s Sarah Hughan presented Break it Down, detailing the online healthcare platform to access erectile dysfunction treatment from LTR Pharma. Take a look:
LTR Pharma completes A$25 million placement to expedite commercialisation of SPONTAN®
LTR Pharma has today announced that it has successfully completed a A$25 million placement to sophisticated and institutional investors to accelerate SPONTAN®’s commercialisation. These funds will accelerate the Company’s progress in the U.S.; increase R&D investment for product portfolio expansion and manufacturing scale-up; and assist with launching an innovative telehealth platform to create a seamless […]
The Australian | LTR Pharma successfully completes $25m cap raise to accelerate novel ED treatment
LTR Pharma’s $25 million placement to support the commercialisation of SPONTAN – its fast-acting nasal spray treatment for erectile dysfunction (ED) – has been reported in The Australia, in a special report titled ‘LTR Pharma successfully completes $25m cap raise to accelerate novel ED treatment.’ Here’s an excerpt: “LTR Pharma chairman Lee Rodne said the […]
Financial Review | Market darling LTR Pharma raises new equity
LTR Pharma’s plans to raise capital via institutional placement were featured in the Financial Review following the Company’s trading halt on Friday. Here’s an excerpt: “Nasal viagra biotech LTR Pharma, whose shares have risen 176 per cent over the past 12 months, was seeking to raise $20 million on Friday via an institutional placement. LTR […]
Dr Boreham’s Crucible | The rise and rise of LTR Pharma
LTR Pharma has been featured in the Stockhead article by respected biotech journalist Tim Boreham titled “The rise and rise of LTR Pharma.” The article highlights the market opportunity for new treatments for Erectile Dysfunction, and LTR Pharma’s strategic path to market in Australia. Here’s an excerpt: “The value of the erectile dysfunction market is […]
Conversation Series | ED Discussions in Primary Care | Dr Tom Silva
The second video from our Conversation Series with Dr Thomas Silva is now live. Dr Silva is a specialist GP and University of Queensland lecturer who brings unique expertise in erectile dysfunction treatment, including experience with complex post-prostate cancer cases. In this conversation, Dr Silva shares his clinical experience with SPONTAN®, discussing how the innovative […]
The Medical Republic | Erectile Dysfunction Telehealth Platform to Launch
LTR Pharma’s exciting new joint venture with Restorative Sexual Health Clinic (RSHC) to launch an online healthcare platform dedicated to men’s health has been featured in The Medical Republic. Here’s an excerpt: ‘𝘔𝘦𝘭𝘪𝘴𝘴𝘢 𝘏𝘢𝘥𝘭𝘦𝘺 𝘉𝘢𝘳𝘳𝘦𝘵𝘵, 𝘧𝘰𝘶𝘯𝘥𝘦𝘳 𝘰𝘧 𝘵𝘩𝘦 𝘙𝘚𝘏𝘊 𝘴𝘢𝘪𝘥: “𝘛𝘩𝘪𝘴 𝘱𝘢𝘳𝘵𝘯𝘦𝘳𝘴𝘩𝘪𝘱 𝘢𝘭𝘪𝘨𝘯𝘴 𝘱𝘦𝘳𝘧𝘦𝘤𝘵𝘭𝘺 𝘸𝘪𝘵𝘩 𝘰𝘶𝘳 𝘮𝘪𝘴𝘴𝘪𝘰𝘯 𝘵𝘰 𝘱𝘳𝘰𝘷𝘪𝘥𝘦 𝘤𝘰𝘮𝘱𝘳𝘦𝘩𝘦𝘯𝘴𝘪𝘷𝘦, 𝘦𝘷𝘪𝘥𝘦𝘯𝘤𝘦-𝘣𝘢𝘴𝘦𝘥 𝘤𝘢𝘳𝘦 𝘵𝘩𝘢𝘵 𝘦𝘯𝘩𝘢𝘯𝘤𝘦𝘴 𝘮𝘦𝘯’𝘴 […]
Joint Venture with Leading Australian Men’s Health Group to Launch Online Platform
LTR Pharma has announced that it has partnered with the Restorative Sexual Health Clinic (RSHC) to establish an innovative online men’s health platform to provide access to healthcare professionals, therapeutic services, and treatments. The joint venture leverages RSHC’s extensive clinical expertise in men’s healthcare and positions LTR Pharma to capitalise on the significant growth in […]
Life Sciences Review | “APAC’s Top Clinical Stage Biopharmaceutical Company”
LTR Pharma has been named “APAC’s Top Clinical Stage Biopharmaceutical Company” and featured in a cover story by global life sciences publication, Life Sciences Review . Featuring Executive Chairman Lee Rodne, the article highlights the Company’s vision of enhancing men’s health and wellbeing by reimagining the treatment landscape for men with Erectile Dysfunction (ED) with […]
Conversation Series | Meet the Expert | Dr Tom Silva
Welcome to LTR Pharma’s latest Conversation Series with Dr Tom Silva – a respected key opinion leader (KOL) in men’s health. Dr Silva is specialist GP and University of Queensland lecturer who brings unique expertise in erectile dysfunction treatment, including experience with complex post-prostate cancer cases. In this conversation, Dr Silva shares clinical perspectives on […]
AUSBIZ | Interview with Lee Rodne
This week, LTR Pharma announced the key findings of its pivotal clinical study of SpontanÒ, demonstrating that the nasal spray is absorbed 470% faster than oral tablets. Executive Chairman, Lee Rodne, recently spoke with @ausbiz anchor Nadine Blayney about the significance of these findings, the Company’s plans to target the US market, and the importance […]
Biotech Dispatch | LTR Pharma says Spontan achieves faster absorption in completed pivotal study
LTR Pharma’s announcement of key results from its pivotal study of SPONTAN has been shared in industry publication, Biotech Daily. Click to read the article.
Stockhead | LTR Pharma’s pivotal trial shows SPONTAN outperforms oral ED tablets
LTR Pharma has been featured in a Special Report in Stockhead, following the announcement of data from the Company’s pivotal study demonstrating that SPONTAN nasal spray is absorbed 470% faster absorption than oral vardenafil. Click here to read the report.
Professor Chung elected President of International Society of Sexual Medicine (ISSM)
Congratulations to LTR Pharma’s Scientific and Clinical Advisor, Professor Eric Chung, on his appointment as President-elect of the International Society of Sexual Medicine (ISSM). The ISSM is a leading international organisation dedicated to advancing the field of sexual medicine. As a trusted source of information, education, and professional development, the ISSM ensures that the latest […]
Conversation Series | Myth Busting about Erectile Dysfunction
This week, Professor Chung shares insights on the common misconceptions about the lived experience of Erectile Dysfunction (ED); myths in relation to treatment of ED, his professional views on the particular issues around the context of men’s sexual health and why he believes SPONTAN® is being welcomed as a potential solution for ED. At LTR […]
Money | The new Viagra alternative you can invest in
Online magazine Money has published an article by Stuart Bromley highlighting the investment opportunity with LTR Pharma, as it progresses the development of SPONTAN nasal spray for the treatment of Erectile Dysfunction (ED). Here’s excerpt: “While most current treatments are off patent and generic, making them quite cheap, it is believed that many consumers looking […]
LTP Secures Global Co-Development Agreement with Aptar Pharma
LTR Pharma has today announced it has entered into a Comprehensive Co-Development Agreement with Aptar Pharma for SPONTAN® for global markets. APTAR is a global leader in the design and manufacturing of a broad range of drug and consumer product dosing, dispensing and protection technologies. APTAR has substantial FDA regulatory expertise and its delivery systems […]